Cargando…
2524. Safety and Pharmacokinetics of PA-001, a New Potential COVID-19 Drug That Targets the S2 Subunit of SARS-CoV-2 Spike Protein, in Healthy Subjects
BACKGROUND: Frequent emergence of new variants of the SARS-CoV-2 virus continues to be a concern in treatment of COVID-19 infection, despite the approval of several drugs in recent years. To address this problem, we identified a new macrocyclic peptide, PA-001, which targets the highly conserved S2...
Autores principales: | Kurasaki, Haruaki, Ohuchi, Masaki, Matsui, Katsuma, Matsumoto, Masatoshi, Nagatomo, Kazutaka, Kawamura, Naoki, Ito, Shoko, Yonemura, Takuma, Chiyoda, Takeshi, Yamamoto, Asuka, Shimoi, Akihito, Masuya, Keiichi, Kitamura, Hidetomo, Murakami, Masato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678873/ http://dx.doi.org/10.1093/ofid/ofad500.2142 |
Ejemplares similares
-
2141. Preclinical Evaluation of PA-001: A Novel, Potential Macrocyclic Peptide-Based Treatment for COVID-19 Which Binds to the S2 Subunit of SARS-CoV-2 Spike Protein
por: Kawamura, Tatsuro, et al.
Publicado: (2023) -
Immune Network Receives First Impact Factor of 2.524
por: Lee, Chong-Kil
Publicado: (2018) -
Partial Characterization of an Anti-Listerial Bacteriocin from
Enterococcus faecium CJNU 2524
por: Yang, Jung-Mo, et al.
Publicado: (2021) -
Fatigue Fracture Analysis on 2524 Aluminum Alloy with the Influence of Creep-Aging Forming Processes
por: Ma, Liyong, et al.
Publicado: (2022) -
2524. Prevalence and Associated Factors of Seroprotection Against Japanese Encephalitis Virus Among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
por: Sudjaritruk, Tavitiya, et al.
Publicado: (2019)